Cefepime-Resistant Pseudomonas aeruginosa
Resistance to extended-spectrum cephalosporins complicates treatment of Pseudomonas aeruginosa infections. To elucidate risk factors for cefepime-resistant P. aeruginosa and determine its association with patient death, we conducted a case–control study in Philadelphia, Pennsylvania. Among 2,529 pat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2011-06-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/17/6/10-0358_article |
| _version_ | 1818543241946988544 |
|---|---|
| author | Ehimare Akhabue Marie Synnestvedt Mark G. Weiner Warren B. Bilker Ebbing Lautenbach |
| author_facet | Ehimare Akhabue Marie Synnestvedt Mark G. Weiner Warren B. Bilker Ebbing Lautenbach |
| author_sort | Ehimare Akhabue |
| collection | DOAJ |
| description | Resistance to extended-spectrum cephalosporins complicates treatment of Pseudomonas aeruginosa infections. To elucidate risk factors for cefepime-resistant P. aeruginosa and determine its association with patient death, we conducted a case–control study in Philadelphia, Pennsylvania. Among 2,529 patients hospitalized during 2001–2006, a total of 213 (8.4%) had cefepime-resistant P. aeruginosa infection. Independent risk factors were prior use of an extended-spectrum cephalosphorin (p<0.001), prior use of an extended-spectrum penicillin (p = 0.005), prior use of a quinolone (p<0.001), and transfer from an outside facility (p = 0.01). Among those hospitalized at least 30 days, mortality rates were higher for those with cefepime-resistant than with cefepime-susceptible P. aeruginosa infection (20.2% vs. 13.2%, p = 0.007). Cefepime-resistant P. aeruginosa was an independent risk factor for death only for patients for whom it could be isolated from blood (p = 0.001). Strategies to counter its emergence should focus on optimizing use of antipseudomonal drugs.
1Current affiliation: Duke University School of Medicine, Durham, North Carolina, USA. |
| first_indexed | 2024-12-11T22:32:46Z |
| format | Article |
| id | doaj.art-309da0175cb94c0d98964467d98d4c3d |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-11T22:32:46Z |
| publishDate | 2011-06-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-309da0175cb94c0d98964467d98d4c3d2022-12-22T00:48:04ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592011-06-011761037104310.3201/eid1706.100358Cefepime-Resistant Pseudomonas aeruginosaEhimare AkhabueMarie SynnestvedtMark G. WeinerWarren B. BilkerEbbing LautenbachResistance to extended-spectrum cephalosporins complicates treatment of Pseudomonas aeruginosa infections. To elucidate risk factors for cefepime-resistant P. aeruginosa and determine its association with patient death, we conducted a case–control study in Philadelphia, Pennsylvania. Among 2,529 patients hospitalized during 2001–2006, a total of 213 (8.4%) had cefepime-resistant P. aeruginosa infection. Independent risk factors were prior use of an extended-spectrum cephalosphorin (p<0.001), prior use of an extended-spectrum penicillin (p = 0.005), prior use of a quinolone (p<0.001), and transfer from an outside facility (p = 0.01). Among those hospitalized at least 30 days, mortality rates were higher for those with cefepime-resistant than with cefepime-susceptible P. aeruginosa infection (20.2% vs. 13.2%, p = 0.007). Cefepime-resistant P. aeruginosa was an independent risk factor for death only for patients for whom it could be isolated from blood (p = 0.001). Strategies to counter its emergence should focus on optimizing use of antipseudomonal drugs. 1Current affiliation: Duke University School of Medicine, Durham, North Carolina, USA.https://wwwnc.cdc.gov/eid/article/17/6/10-0358_articleresistancecefepimePseudomonas aeruginosarisk factorsoutcomesbacteria |
| spellingShingle | Ehimare Akhabue Marie Synnestvedt Mark G. Weiner Warren B. Bilker Ebbing Lautenbach Cefepime-Resistant Pseudomonas aeruginosa Emerging Infectious Diseases resistance cefepime Pseudomonas aeruginosa risk factors outcomes bacteria |
| title | Cefepime-Resistant Pseudomonas aeruginosa |
| title_full | Cefepime-Resistant Pseudomonas aeruginosa |
| title_fullStr | Cefepime-Resistant Pseudomonas aeruginosa |
| title_full_unstemmed | Cefepime-Resistant Pseudomonas aeruginosa |
| title_short | Cefepime-Resistant Pseudomonas aeruginosa |
| title_sort | cefepime resistant pseudomonas aeruginosa |
| topic | resistance cefepime Pseudomonas aeruginosa risk factors outcomes bacteria |
| url | https://wwwnc.cdc.gov/eid/article/17/6/10-0358_article |
| work_keys_str_mv | AT ehimareakhabue cefepimeresistantpseudomonasaeruginosa AT mariesynnestvedt cefepimeresistantpseudomonasaeruginosa AT markgweiner cefepimeresistantpseudomonasaeruginosa AT warrenbbilker cefepimeresistantpseudomonasaeruginosa AT ebbinglautenbach cefepimeresistantpseudomonasaeruginosa |